Invizius Mobile Laboratory
A mobile laboratory for clinical research
Supporting better health for the future
Invizius and Manchester University NHS Foundation Trust are conducting, with EMS Healthcare's support, the largest kinetic biomarker expression study on Haemodialysis patients anywhere in the world.
Invizius' aim is to reduce the inflammation that the patients experience which will hopefully lead to better outcomes and the patient feeling better and living longer. EMS Healthcare are proud to be supporting Invizius by providing:
- A mobile lab to rapidly process and cryopreserve the blood samples of over 600 volunteers. This enables “immune snapshots” to be taken from dialysis patients for the first time
- A team of technicians who drive the lab to various hospitals across North-West England, liaising with clinical staff to ensure fragile immune biomarkers are processed
Client testimonial
EMS Healthcare's solution enabled a “world first” insight into the dialysis inflammation status of patients, designing a mobile lab that can rapidly perform all the required processing and preservation required to deliver this high intensity project. The mobile solution has proved to be a cost efficient and highly effective alternative to setting up static labs at multiple collection sites.
Dr Magnus Nicolson
Chief Operating Officer at Invizius
Invizius mobile laboratory
Tailor-made for every partner’s unique set of challenges
This groundbreaking project with Invizius faced a unique set of challenges that the collaboration is designed to overcome – delivering a compelling example of a successful public/private partnership.
At the Manchester Foundation Trust Satellite Dialysis Unit based in Tameside, EMS Healthcare's clinical technicians process bloods from dialysis patients. The samples are then taken back to EMS Healthcare's HQ in Cheshire on board the mobile laboratory. Here, they are stored at minus 80 degrees Celsius, before being sent on to a laboratory in Glasgow for biomarker analysis.
Due to the technical challenges, no-one had ever conducted a kinetic study over the time course of dialysis and the mobile solution enables a “world first” insight into the dialysis inflammation status of patients.
